The Zhitong Finance App learned that Hainan Province issued an implementation plan for three children. The plan mentions policies on assisted reproduction. According to data, more than a dozen provinces, including Fujian, Jiangsu, Guangdong, Beijing, Jiangxi, and Sichuan, have introduced policies to implement three children, all of which mention assisted reproduction. According to relevant estimates, it is estimated that by 2023, the overall infertility rate among people of childbearing age in China will reach 18.2%, and the assisted reproduction industry has broad scope for development. Open Source Securities estimates that the annual compound rate for 2018-2023 is 9.64%. By 2023, the market size of assisted reproduction is expected to increase to 40 billion yuan, which is expected to exceed 100 billion dollars in the long term.
On June 23, Hainan Province issued an implementation plan for three children. The plan mentions policies relating to assisted reproduction. Hainan Province proposed to lay out a reasonable human assisted reproductive technology service system, strengthen supervision of human assisted reproductive technology services, strictly regulate the application of relevant technology, standardize infertility diagnosis and treatment services, and meet the reproductive health needs of the masses.
Up to the latest, more than a dozen provinces, including Fujian, Jiangsu, Guangdong, Beijing, Jiangxi, and Sichuan, have introduced policies to implement three children, all of which mention assisted reproduction. Meanwhile, Beijing, Jiangxi, Hunan, Sichuan, Hubei and other places have also announced plans to include assisted reproductive technology projects in health insurance.
The accessibility and quality of infertility interventions remains a major challenge in many countries around the world. The diagnosis and treatment of infertility are often not prioritized in national population and development policies and reproductive health strategies, and public health funding is rarely available. However, in China, whether it is the development of medical technology or the active implementation of the “second child” or even “three child” population policies introduced continuously, it shows that in China's general environment, the importance attached to fertility issues has risen to a national level.
According to data released by the National Health Commission and the China Population Association, the infertility rate of couples of childbearing age in China has climbed from 2.5%-3% 20 years ago to around 12%-15% in recent years, and there are about 50 million people who are infertile. Moreover, in the past ten years, the infertility rate of couples of childbearing age in China has continued to rise at an accelerated pace.
According to Frost & Sullivan's data, in 2014-2018, China's assisted reproductive services market increased from 14 billion yuan to 25.2 billion yuan, with a compound annual growth rate of 15.8%. However, the penetration rate of assisted reproduction in China in 2018 was only 7.0%, far lower than the US penetration rate of 30.2% during the same period. According to estimates, it is estimated that by 2023, the overall infertility rate among people of childbearing age in China will reach 18.2%, and the assisted reproduction industry has broad scope for development.
The Open Source Securities Research Institute estimates that the annual compound rate for 2018-2023 is 9.64%. By 2023, the market size of assisted reproduction is expected to increase to 40 billion yuan, which is expected to exceed 100 billion dollars in the long term.
Guotai Junan pointed out that with the postponement of childbearing age, the liberalization of fertility policies, and the increase in the prevalence of infertility, the number of patients with infertility couples in need of assisted reproduction services in China is huge and constantly expanding. At the same time, as awareness and ability to pay for assisted reproduction continue to increase, China's assisted reproductive services market will continue to grow rapidly.
Related concept stocks:
Jin Xin Reproduction (01951): High quality private assisted reproduction institutions with technical barriers and license barriers;
Beckon Medical (02170): It has an integrated genetic testing platform covering the entire reproductive cycle. The company's PGT-A kit is the only certified domestic third-generation IVF genetic testing product. Subsequent product certification is expected to continue to increase performance;
Edigal Palace (00286): Leading confinement service center segmentation circuit; demand for confinement services, the main business, is strong, and the new asset-light model is expanding at an accelerated pace. Revenue reached HK$632 million in 2021, an increase of 9.26% over the previous year;
Capcom Biology (300639.SZ): Accelerate the deployment of prenatal diagnosis and neonatal screening, and it is expected that genetic testing products for poverty and deafness will continue to be rapidly released;
Shengnuo Biotech (688117.SH): The company's self-developed generic drug, Garnierick, is mainly used to treat infertility in women. It is an assisted reproductive drug. Currently, this variety has been declared domestically and is awaiting approval.